VMY-1-103

VMY-1-103 is an inhibitor for cyclin/Cdk complex, that arrests the cell cycle at G1 phase. VMY-1-103 reduces mitochondrial membrane potential, induces p53 phosphorylation and and PARP cleavage, activates caspase-3, and thus induces apoptosis in prostate cancer cell LNCaP .


Cat. No.: EX-A10370	Purity: >98%

	Chemical structure of VMY-1-103

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
5mg	886	Inquire
10mg	1392	Inquire
25mg	get quote	Inquire
50mg	get quote	Inquire
100mg	get quote	Inquire
500mg	get quote	Inquire

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	1209002-43-6
Purity	>98%
Formula	C34H42ClN9O4S
Mol Weight	708.273
State	solid powder
Solubility	Soluble in DMSO
Shelf Life	>3 years if stored properly
Storage	Powder 4℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Ringer L, et al., VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells. Cancer Biol Ther. 2010 Aug 15;10(4):320-5.
CoA	CoA of VMY-1-103

Smiles:	O=C(NCCNS(=O)(C1=C2C=CC=C(N(C)C)C2=CC=C1)=O)C3=CC=C(NC4=C5N=CN(C(C)C)C5=NC(N[C@@H](CO)C(C)C)=N4)C=C3Cl


		Search